Feds Announce Effort to Stop Inappropriate Use of Antipsychotic Drugs in Nursing Homes

Did you know that almost half of all dementia patients living in nursing homes are given antipsychotic drugs?

Off-Label Use Of Antipsychotics 

Antipsychotics, which include drugs like Clozaril (clozapine), Abilify (aripiprazole), Seroquel (quetiapine), Zyprexa (olanzapine), and Risperdal (risperidone), are not approved for the treatment of dementia, but are being used, off-label, in nursing homes to treat a host of unapproved diagnoses, including dementia.

There are no drugs currently approved by the U.S. Food & Drug Administration (FDA) to manage agitation, aggression, and hallucinations in the elderly and those diagnosed with Alzheimer’s disease and dementia. Risks include diabetes, movement disorders that can become permanent, pneumonia, stroke, weight gain, and sudden cardiac death.

Government Steps Up

Federal regulators announced a multiyear initiative to slash the inappropriate use of antipsychotic drugs on nursing home residents, saying that nearly 40 percent of residents with dementia were receiving the powerful sedatives though they did not have a condition that would warrant it.

The US Centers for Medicare & Medicaid Services said it was aiming to reduce the use of antipsychotic drugs in nursing home residents by 15 percent by the end of this year, through training of nursing home staff and of state inspectors on alternatives to using antipsychotics to quell aggressive and agitated behavior among people with dementia.

The plan, announced by CMS Acting Administrator Marilyn Tavenner, is a collaborative effort involving federal and state governments, nursing homes, healthcare providers, advocacy groups, and caregivers.

A 2011 Department of Health and Human Services Office of the Inspector General (OIG) report revealed that about 14% of all nursing home residents with Medicare had claims for antipsychotics; 88% of the atypical antipsychotics prescribed off-label were for dementia.

According to the CMS, the rising practice of unnecessarily treating the elderly with antipsychotics represents a significant change in how dementia care is handled. The CMS press release also stated that in 2010, over 17% of all nursing home patients received daily doses of antipsychotics and at greater than the recommended dosage.

The initiative, entitled, the “Partnership to Improve Dementia Care” includes launching a new nursing home staff training program focused on high quality care and abuse prevention; ensuring data on antipsychotic use in nursing homes is available on Nursing Home Compare, effective July 2012; emphasizing nonpharmacological alternatives over antipsychotics for nursing home residents such as consistent staff assignments, increased exercise and outdoor time, acute and chronic pain oversight and management, and planning individualized activities.

Senators Charles Grassley (Republican-Iowa) and Herb Kohl (Democrat-Wisconsin) requested the report and have long been urging the CMS to look at antipsychotic use in nursing homes.

 



, , , , , ,

No comments yet.

Leave a Reply

GET HELP NOW!
  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Underground Railway Dust May Pose Health Risk

Travelling or working on an underground railway for sustained period of time could have health implications due to concentrations of metal-rich microscopic dust particles.

New Study Helps Understand Why Health Care Costs On The Rise

Although many believe is it medical malpractice suites that are causing the increase in the health care costs, it is actually the fear of them that is partly to blame. Doctors are ordering unnecessary tests and procedures for fear of a patient filing a claim down the road

FDA Issues New Warnings Concerning Tolvaptan

The FDA has issued a drug safety communication concerning Tolvaptan, a selective vasopression V2-receptor antagonist used in heart failure patients to treat clinically significant hypervolemic and euvolemic hyponatremia.

New Antiepileptic Drug Causes Blue Discoloration And Vision Trouble

An antiepileptic drug to hit the market has been known to cause vision troubles and skin discoloration. Almost all patients experienced gray/blue skin discoloration who had been taking the pill for two years. More information is needed to better understand the occurrences.

Medical Mattresses Pose Risk Of Infection And Contamination

The FDA warns that medical mattresses may not be as clean as once perceived. Routine checks on mattresses are advised as any rips, tears, or excessive wear alter the efficacy. The medical mattresses as well as the covers have an expected life depending on the manufacturer, which should not go unnoticed.

Latest Medical Device Injury News

Women 30% More Likely To Need Repeat Hip Implant Surgery

Doctors traditionally believed the larger the size of the implant, the more protective it was against failure, according to Sedrakyan. However, he said his study found regardless of size, women had a higher rate of revision occurrence, so some other factor besides the actual implants may be leading to this effect.

Transvaginal Mesh Lawsuits – Who Is At Fault?

For some women a pelvic transvaginal mesh product has been a god sent.  To be able to resume a full active life, without the worry of a leaky bladder, is a true miracle for some women.  And, this only became possible with the help of pelvic mesh. The mesh is most commonly used after pelvic [...]

Metal-on-Metal Hip Implants Cause Soft Tissue Damage Says FDA

Hip joint deterioration can lead to pain, stiffness or difficulty walking. When these symptoms do not respond to conservative treatment, such as physical therapy, patients may be advised to undergo total hip replacement or hip resurfacing. As part of this treatment, they may receive a “metal-on-metal” hip implant in which the “ball and socket” of [...]

Ethicon Recalls Surgical Stapler

The FDA has announced a voluntary global recall of more than 157,000 Ethicon surgical staplers, due to problems with incomplete firing strokes that may cause faulty staple formation, potentially resulting in painful and severe internal complications for the patient. An Ethicon surgical stapler recall was first announced in August, after reports surfaced where surgeons experienced [...]

Another Device Maker Investigated By DOJ

Earlier this month, cardiovascular device maker Abiomed announced that the US Attorney’s Office was investigating the company’s marketing and labeling of the Impella 2.5 circulatory support device. According to Forbes, the announcement confirmed rumors that had been circulating for at least two weeks, though in the press release the company said it had just been [...]